Acne Vulgaris
CollaGenex Pharmaceuticals Initiates 40 mg Cohort in the Phase II Dose-Finding Study of Incyclinide for the Treatment of Acne
Published in Health Business Week, April 13th, 2007
CollaGenex Pharmaceuticals, Inc. (NASDAQ:CGPI) announced that it has initiated enrollment in a 40 mg cohort in its Phase II double-blinded, placebo-controlled, dose-finding clinical trial to determine the appropriate dose for Phase III testing of incyclinide in the treatment of acne. The 40 mg cohort will enroll 100 patients with moderate-to-severe acne at 13 investigational centers across the United States. The placebo-controlled study will evaluate a daily 40 mg dose of incyclinide over a 12 week period.
Klaus Theobald, M.D., Ph.D., chief medical officer of CollaGenex, said, "We are extremely encouraged that the analysis of the 5, 10, and 20 mg cohorts demonstrated a...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
Source: Health Business Week (2007-04-13)
More Articles from Health Business Week
- AARP
AARP Teams With Iowa Business, Industry, Education and Labor to Spur Action on Health Care, Long-Term Financial Security - Abbott
Abbott Named to DiversityInc's 'Top 50 Companies for Diversity' List - Abiomed, Inc.
Abiomed Expands Availability of Impella Circulatory Support Technologies with Regulatory Approvals in India - Abiomed, Inc.
Abiomed, Inc. Closes Sale of Common Stock in Public Offering - Achillion Pharmaceuticals, Inc.
Achillion Reports 2006 Fourth Quarter and Year-End Financial Results - Advanced Medical Institute Inc.
Advanced Medical Institute Inc. Shares Cleared for Trading on the OTCBB - More from this issue of Health Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
